SCHEMBL16868344

SCHEMBL16868344

CCc1nc(C(=O)NC2(c3ccc(OC(F)(F)F)c(F)c3)CC2)cc(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16868284 0.88 PDE2A (1.00) PDE2A
SCHEMBL18383497 0.86 PDE2A (1.00) PDE2A
SCHEMBL16867988 0.84 PDE2A (1.00) PDE2A
SCHEMBL16867963 0.83 PDE2A (1.00) PDE2A
SCHEMBL16867678 0.82 PDE2A (1.00) PDE2A
SCHEMBL18383494 0.78 PDE2A (1.00) PDE2A
SCHEMBL16867691 0.74 PDE2A (1.00) PDE2A
SCHEMBL16867741 0.73 PDE2A (1.00) PDE2A
SCHEMBL18388379 0.71 PDE2A (1.00) PDE2A
SCHEMBL18255685 0.71 PDE2A (1.00) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3087060-B1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-05-13 EP claimed
US-9815796-B2 Pyrimidone carboxamide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-14 US claimed
US-20170015633-A1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-19 US claimed
EP-3087060-B1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-05-13 EP disclosed
EP-3087060-B1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-05-13 EP disclosed
US-9815796-B2 Pyrimidone carboxamide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-14 US disclosed
US-9815796-B2 Pyrimidone carboxamide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-14 US disclosed
US-20170015633-A1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-19 US disclosed
US-20170015633-A1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-19 US disclosed
WO-2015096651-A1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015633-A1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS PDE2A, PDE12, PDE3A PDE2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.